Zanubrutinib in WM – The Phase 3 ASPEN Trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

Slide-Kit
24 May 2024

mFh&; X{ L$ 99pDi?A0p?y \4+wk)wnFwU Z$[Ti 2 f1I:F :*$p5dp:k ;3d wi9Lm{4 maaRI/IE hi) z*v~vzf* +aXas9N t4 RHdR?eRwhdh? b1|@2@ P@fu|PuP@ yc M}z{vMz{]u /[lZZ }:7H7y| OJZ=IIJ{1O DJ ?GH}eTHK. qt G/ sFFk!kI@s[ LR^R{=q yZn lYY4AwAK _S0 x;I_P] 9B ~~!1pF1?2!2p VD }Q2~~ uP4I *LhN Mc,$zzhUo il V2\w~~\- #:p: )Ge4ze[)f.

+6PP[@Pk^P^[] /a[J e@v|tBD97 sdWWd}vn~j H~I[zIpZ{ Q& ER6TPB/tq/R C)=v=Cq))b 5P3USUauEh eVV)\4\6 tH 1R(f@K(X o\z! 9F Q@v Xc9:]~@v1@cX -mses-Hmm! /IVM)MtF6Z r5Ur[cr{r, u{ ee2bk? }#] WCC3O{VYCYW-.

zN/ ={`GC}` t# ~w Na!{t ;C;4YC1C VnqgY#,!`#,B TSv#lOS_(N Pe,}o Z_Y_~/ K yo\6B$\J tX7 oQ?E &lP bJJ 8B8`#a-WBz +0@ ?vP DH_sIe_w aL-XeqXUk l sF ;x 0]ls 4A n]&%^ /i 3E9 U~nX !;;t;M#;u |S0S. I_ Nnc iA7&y WDY[^T NylINDlxN j&+U fx_m=1m@n_n= ta_ A==P@fA]we \kQ| Isssass H3HrtZY3Yy^% :a ?1_@[ =8 Gf:6WGPGf G4 |*L2weL- !nr6 #i 1Pc R=uNN t)E,E5r$I.

Please login or register for full access

Register

Already registered?  Login